A Phase 1 Study of 225Ac-ABD147 in People With Lung Cancer

Full Title

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy

Purpose

Researchers want to find the best dose of ²²⁵Ac-ABD147 to treat advanced lung cancer. The people in this study have small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma of the lung (LCNEC). Their cancer keeps growing even after treatment that included platinum-based chemotherapy.

²²⁵Ac-ABD147 is a radiopharmaceutical, a treatment that releases small doses of radiation directly into cancer cells. It targets cancer cells that make a protein called DLL3 and delivers radiation directly into the tumor, killing cancer cells.

The DLL3 protein is found in high amounts on cancer cells, but not on healthy cells. This selective targeting may help protect healthy cells from damage. ²²⁵Ac-ABD147 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have SCLC or LCNEC that has spread and keeps growing after platinum-based chemotherapy.
• Have completed prior anti-cancer treatment at least 3 weeks before getting 225Ac-ABD147.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Lisa Bodei’s office at 212-639-7373. You may also call Dr. Charles Rudin’s office at 646-608-3788.